Adverse Effects of Oral Hypoglycemic Agents and Adherence to them among Patients with Type 2 Diabetes Mellitus in Nepal

Authors

  • Jyoti Tara Manandhar Shrestha Kathmandu University School of Medical Sciences (KUSMS), Chaukot, Dhulikhel
  • Himal Shrestha Kathmandu University
  • Miyasha Prajapati Kathmandu University
  • Astha Karkee Kathmandu University
  • Aman Maharjan Kathmandu University

Keywords:

Adverse effects, Type 2 diabetes mellitus, Hypoglycemia, Hypoglycemic agents, Patient adherence

Abstract

Introduction: Oral hypoglycemic agents (OHAs) are the most common drugs used in Type 2 Diabetes Mellitus. There are various established adverse effects related to their use including hypoglycemia, weight gain, gastrointestinal disturbance, lactic acidosis, and fluid retention. However, the pattern of adverse effects related to OHAs in Nepalese patients still needs to be explored. Our study aims to determine the pattern of adverse effects resulting from the use of OHAs among Type 2 Diabetes mellitus patients and their adherence to the medication.

Methods: All diabetic patients who met the inclusion criteria were enrolled in the study. After informed consent, patients were interviewed and evaluated as per the designed proforma. They were mainly studied for common drug used, adverse effects of the drugs, occurrence of hypoglycemia, and adherence to treatment.

Results: The study comprised of 183 patients with mean age of 58.73 years (SD = 12.95). Fifty-six (30.6%) patients said that they developed adverse effects of drugs but only 21 (11.5%) of them reported to their treating physician. Most common adverse effect were related to central nervous system such as tingling sensation of hands and feet, dizziness, drowsiness, etc. Though 91 (49.7%) patients had developed symptoms suggestive of hypoglycemia, only 31 (16.9%) knew that it was due to hypoglycemia. Majority of the patients (n = 143, 78.1%) administered the drugs as prescribed by the physician. Among the defaulters, the most important reasons for failure to properly administer the drugs was forgetfulness in 82.5% (n = 33, N = 40) of cases. Among the study variables family history of chronic illness (p = 0.046) and information about adverse effects from physician (p = 0.001) had a significant relationship with incidence of adverse effects. Whereas none of them had a significant relationship with adherence to hypoglycemic medication.

Conclusion: The incidence of adverse effects was high with hypoglycemia occurring in 49.7% of the cases, though only one-third of them recognized it to be due to hypoglycemia, in the patients with Type 2 Diabetes Mellitus. Family history of chronic illness and information about adverse effects from the physician had significant relationship with the incidence of adverse effects of hypoglycemic treatment. 

Journal of Lumbini Medical College

 Vol 5, No 1, Jan-June 2017, page: 34-40

DOI: https://doi.org/10.22502/jlmc.v5i1.126

Downloads

Download data is not yet available.
Abstract
5114
PDF
1397

Downloads

Published

2017-07-05

How to Cite

Manandhar Shrestha, J. T., Shrestha, H., Prajapati, M., Karkee, A., & Maharjan, A. (2017). Adverse Effects of Oral Hypoglycemic Agents and Adherence to them among Patients with Type 2 Diabetes Mellitus in Nepal. Journal of Lumbini Medical College, 5(1), 34–40. Retrieved from https://nepjol.info./index.php/JLMC/article/view/17685

Issue

Vol. 5 No. 1 (2017)

Section

Original Research Articles

License

The Journal of Lumbini Medical College (JLMC) publishes open access articles under the terms of the Creative Commons Attribution(CC BY) License which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

JLMC requires an exclusive licence allowing to publish the article in print and online.

The corresponding author should read and agree to the following statement before submission of the manuscript for publication,

License agreement
In submitting an article to Journal of Lumbini Medical College (JLMC) I certify that:

  1. I am authorized by my co-authors to enter into these arrangements.
  2. I warrant, on behalf of myself and my co-authors, that:
    • the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
    • I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JLMC are not in breach of any other obligation;
    • the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
    • I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
  3. I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. If the law requires that the article be published in the public domain, I/we will notify JLMC at the time of submission, and in such cases the article shall be released under the Creative Commons 1.0 Public Domain Dedication waiver. For the avoidance of doubt it is stated that sections 1 and 2 of this license agreement shall apply and prevail regardless of whether the article is published under Creative Commons Attribution License 4.0 or the Creative Commons 1.0 Public Domain Dedication waiver.
  4. I, and all co-authors, agree that, if the article is editorially accepted for publication in JLMC, data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.

Please visit Creative Commons web page for details of the terms.